Reductions in HbA@c with canagliflozin @ and @ mg versus placebo were -@ % ( @ % CI -@ , -@ ; -@ mmol/mol -LSB- @ % CI -@ , -@ -RSB- ; P < @ ) and -@ % ( @ % CI -@ , -@ ; -@ mmol/mol -LSB- @ % CI -@ , -@ -RSB- ; P < @ ) at @ weeks and -@ % ( @ % CI -@ , -@ ; -@ mmol/mol -LSB- @ % CI -@ , -@ -RSB- ) and -@ % ( @ % CI -@ , -@ ; -@ mmol/mol -LSB- @ % CI -@ , -@ -RSB- ) at @ weeks .